ReviewWorld journal of gastroenterology2023
Bile acids and their receptors: Potential therapeutic targets in inflammatory bowel disease.
Review in World journal of gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Role and progression of bile acid metabolism in mediating Th17/Treg homeostasis in inflammatory bowel disease.iScience · 2026Review
- Cross-kingdom microbial interactions in the gut during inflammatory bowel disease.Journal of translational medicine · 2026Review
- Expression Profiles, Biological Functions and Clinical Significance of Circular RNAs in Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- Secondary bile acid lithocholic acid ameliorates colitis-like inflammation in a human intestine-on-chip system.Frontiers in immunology · 2026Article
- Advances in research on the effects of bile acids and their receptors on intestinal function.Frontiers in nutrition · 2026Review
- Balance between bile acid conjugation and hydrolysis activity can alter outcomes of gut inflammation.Nature communications · 2025Article
- Advances in intestinal epithelium and gut microbiota interaction.Frontiers in microbiology · 2025Review
- Effects of choline metabolite-trimethylamine N-oxide on immunometabolism in inflammatory bowel disease.Frontiers in immunology · 2025Review
- Global research trends on the interaction between gut microbiome and bile acids: a bibliometric and visualized analysis.Frontiers in cellular and infection microbiology · 2025Article
- Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Navigating new horizons in inflammatory bowel disease: Integrative approaches and innovations.World journal of gastroenterology · 2024Article
- Causality of genetically determined blood metabolites on inflammatory bowel disease: a two-sample Mendelian randomization study.Scientific reports · 2024Article
- Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load.Cell reports · 2024Article
- Regulation of bile acids and their receptor FXR in metabolic diseases.Frontiers in nutrition · 2024Review
- Recent advances in gut microbiota and thyroid disease: pathogenesis and therapeutics in autoimmune, neoplastic, and nodular conditions.Frontiers in cellular and infection microbiology · 2024Review
- Targeting Farnesoid X Receptor in Tumor and the Tumor Microenvironment: Implication for Therapy.International journal of molecular sciences · 2023Review
- Houttuynia cordata thunb. alleviates inflammatory bowel disease by modulating intestinal microenvironment: a research review.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic and recurrent inflammatory disorders of the gastrointestinal tract caused by a complex interplay between genetics and intestinal dysbiosis are called inflammatory bowel disease. As a result of the interaction between the liver and the gut microbiota, bile acids are an atypical class of steroids produced in mammals and traditionally known for their function in food absorption. With the development of genomics and metabolomics, more and more data suggest that the pathophysiological mechanisms of inflammatory bowel disease are regulated by bile acids and their receptors. Bile acids operate as signalling molecules by activating a variety of bile acid receptors that impact intestinal flora, epithelial barrier function, and intestinal immunology. Inflammatory bowel disease can be treated in new ways by using these potential molecules. This paper mainly discusses the increasing function of bile acids and their receptors in inflammatory bowel disease and their prospective therapeutic applications. In addition, we explore bile acid metabolism and the interaction of bile acids and the gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.